- Home
- WNEB vs URGN Comparison
WNEB vs URGN Comparison
Compare WNEB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- URGN
- Stock Information
- Founded
- WNEB 1853
- URGN 2004
- Country
- WNEB United States
- URGN United States
- Employees
- WNEB N/A
- URGN N/A
- Industry
- WNEB Savings Institutions
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- URGN Health Care
- Exchange
- WNEB Nasdaq
- URGN Nasdaq
- Market Cap
- WNEB 195.7M
- URGN 831.6M
- IPO Year
- WNEB N/A
- URGN 2017
- Fundamental
- Price
- WNEB $10.73
- URGN $19.22
- Analyst Decision
- WNEB Buy
- URGN Strong Buy
- Analyst Count
- WNEB 3
- URGN 8
- Target Price
- WNEB $11.00
- URGN $29.00
- AVG Volume (30 Days)
- WNEB 85.8K
- URGN 1.3M
- Earning Date
- WNEB 07-22-2025
- URGN 08-07-2025
- Dividend Yield
- WNEB 2.53%
- URGN N/A
- EPS Growth
- WNEB N/A
- URGN N/A
- EPS
- WNEB 0.59
- URGN N/A
- Revenue
- WNEB $76,036,000.00
- URGN $91,871,000.00
- Revenue This Year
- WNEB N/A
- URGN $39.80
- Revenue Next Year
- WNEB $7.36
- URGN $108.94
- P/E Ratio
- WNEB $18.78
- URGN N/A
- Revenue Growth
- WNEB 2.15
- URGN 8.98
- 52 Week Low
- WNEB $7.38
- URGN $3.42
- 52 Week High
- WNEB $11.68
- URGN $19.69
- Technical
- Relative Strength Index (RSI)
- WNEB 60.17
- URGN 76.29
- Support Level
- WNEB $11.02
- URGN $18.37
- Resistance Level
- WNEB $11.41
- URGN $19.36
- Average True Range (ATR)
- WNEB 0.36
- URGN 1.03
- MACD
- WNEB 0.08
- URGN 0.25
- Stochastic Oscillator
- WNEB 54.98
- URGN 91.26
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.